US Patent

US10940128 — Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same

Method of Use · Assigned to Cydex Pharmaceuticals Inc · Expires 2030-06-14 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of melphalan and a cyclodextrin derivative, and methods of making and using these compositions.

USPTO Abstract

The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.

Drugs covered by this patent

melphalan-hydrochloride (MELPHALAN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3086`	—	melphalan-hydrochloride

Patent Metadata

Patent number: US10940128
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Cydex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.